What is HC Wainwright’s Estimate for CRVS FY2028 Earnings?

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) – Equities researchers at HC Wainwright lowered their FY2028 earnings per share (EPS) estimates for Corvus Pharmaceuticals in a research report issued on Wednesday, March 26th. HC Wainwright analyst S. Lee now anticipates that the company will post earnings per share of $0.11 for the year, down from their prior forecast of $0.14. HC Wainwright currently has a “Buy” rating and a $11.00 target price on the stock. The consensus estimate for Corvus Pharmaceuticals’ current full-year earnings is ($0.63) per share. HC Wainwright also issued estimates for Corvus Pharmaceuticals’ FY2029 earnings at $0.44 EPS.

Separately, Oppenheimer restated an “outperform” rating and issued a $15.00 target price (up from $14.00) on shares of Corvus Pharmaceuticals in a report on Wednesday. One research analyst has rated the stock with a sell rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $15.67.

Corvus Pharmaceuticals Stock Up 0.3 %

NASDAQ CRVS opened at $3.38 on Thursday. The stock has a market cap of $217.19 million, a price-to-earnings ratio of -3.63 and a beta of 0.91. Corvus Pharmaceuticals has a fifty-two week low of $1.30 and a fifty-two week high of $10.00. The business has a fifty day moving average of $4.61 and a 200-day moving average of $6.05.

Corvus Pharmaceuticals (NASDAQ:CRVS) last released its quarterly earnings results on Tuesday, March 25th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.06).

Institutional Investors Weigh In On Corvus Pharmaceuticals

Several hedge funds have recently modified their holdings of the stock. Avity Investment Management Inc. raised its stake in Corvus Pharmaceuticals by 7.6% during the fourth quarter. Avity Investment Management Inc. now owns 29,680 shares of the company’s stock worth $159,000 after purchasing an additional 2,100 shares during the period. Geode Capital Management LLC raised its position in shares of Corvus Pharmaceuticals by 0.7% in the 4th quarter. Geode Capital Management LLC now owns 566,863 shares of the company’s stock worth $3,034,000 after buying an additional 3,854 shares during the period. Renaissance Technologies LLC grew its position in Corvus Pharmaceuticals by 1.1% during the fourth quarter. Renaissance Technologies LLC now owns 390,688 shares of the company’s stock valued at $2,090,000 after acquiring an additional 4,100 shares during the period. Nwam LLC increased its stake in Corvus Pharmaceuticals by 54.2% during the fourth quarter. Nwam LLC now owns 15,500 shares of the company’s stock worth $83,000 after acquiring an additional 5,450 shares during the last quarter. Finally, Virtus ETF Advisers LLC purchased a new position in shares of Corvus Pharmaceuticals in the 4th quarter worth about $47,000. 46.64% of the stock is owned by institutional investors and hedge funds.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.